Beryl Drugs (BOM:524606) 3-Year Revenue Growth Rate : 28.60% (As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

What is Beryl Drugs 3-Year Revenue Growth Rate?

Beryl Drugs's Revenue per Share for the three months ended in Dec. 2023 was ₹14.94.

During the past 12 months, Beryl Drugs's average Revenue per Share Growth Rate was 22.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 28.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 10.40% per year. During the past 10 years, the average Revenue per Share Growth Rate was 3.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Beryl Drugs was 28.60% per year. The lowest was -9.50% per year. And the median was 4.90% per year.

Competitive Comparison of Beryl Drugs's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Beryl Drugs's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beryl Drugs's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beryl Drugs's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Beryl Drugs's 3-Year Revenue Growth Rate falls into.

Beryl Drugs 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Beryl Drugs (BOM:524606) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Beryl Drugs 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Beryl Drugs's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Beryl Drugs (BOM:524606) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beryl Drugs Ltd (BOM:524606) » Definitions » 3-Year Revenue Growth Rate

Traded in Other Exchanges

N/A

Address

133, Kanchan Bagh, Ground Floor, Indore, MP, IND, 452001

Website

http://www.beryldrugs.com

Beryl Drugs Ltd is a pharmaceutical company principally engaged in the manufacturing and marketing of allopathic pharmaceutical preparations. It also provides contract manufacturing services and veterinary products. It offers manufacturing options for product requirements like small-volume injectables in liquid form, small-volume injectables in dry powder form, eye and ear drops, intravenous fluids in poly pack and glass bottles, and veterinary medicines. The company earns the majority of its revenue from the sale of Bulk Drugs.

Beryl Drugs (BOM:524606) Headlines

No Headlines